Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 2/2014

01-06-2014 | Erratum

Erratum to: Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer

Authors: Luís León, Roberto García-Figueiras, Cristina Suárez, Antonia Arjonilla, Javier Puente, Blanca Vargas, Maria José Méndez Vidal, Carmen Sebastiá

Published in: Targeted Oncology | Issue 2/2014

Login to get access

Excerpt

Erratum to: Targ Oncol (2014) 9:9–24 …
Metadata
Title
Erratum to: Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer
Authors
Luís León
Roberto García-Figueiras
Cristina Suárez
Antonia Arjonilla
Javier Puente
Blanca Vargas
Maria José Méndez Vidal
Carmen Sebastiá
Publication date
01-06-2014
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 2/2014
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-014-0317-x

Other articles of this Issue 2/2014

Targeted Oncology 2/2014 Go to the issue

Original Research

Anti-leukemic response of a NSAID, tolfenamic acid

Review

Market access of cancer drugs in European countries: improving resource allocation

Original Research

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT

Day-to-Day Practice

A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment

Review

The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer

Original Research

Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits